Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ AMRA Medical, a digital health company delivering a new standard in body composition analysis through rapid whole-body magnetic resonance.
Randolph, Massachusetts (PRWEB) April 21, 2022 The FSHD Society announced that it is launching a collaboration involving the FSHD Clinical Trial Research
03.03.2022 - – Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 – – On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022 – – Conference call scheduled for .